ArticlePakistan journal of medical sciences2026
Overcoming resistance barriers: Using the salvage therapy of Ceftazidime-Avibactam and Aztreonam for difficult-to-treat gram-negative infections at a tertiary care hospital in Karachi-A retrospective cohort pilot.
Article in Pakistan journal of medical sciences, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background & Objective: Rise of carbapenem resistance poses a major global health challenge, particularly in Pakistan where treatment options for Gram-negative carbapenem-resistant Enterobacteriaceae (CRE), are extremely limited. Last-resort agents such as colistin, tigecycline, and fosfomycin are constrained by toxicity and emerging resistance. Aztreonam, active against metallo-β-lactamase-producing organisms, is often unavailable or unaffordable. At Indus Hospital and Health Network (IHHN), Ceftazidime-Avibactam (CAZ-AVI) combined with Aztreonam (ATM) was used as salvage therapy between September 2023 and September 2024. The study aimed to evaluate outcomes of using CAZ-AVI with Aztreonam in patients with CRE. Methodology: This retrospective cohort study was conducted at IHHN from September 2023 to September 2024. Patients with carbapenem-resistant infections treated with CAZ-AVI + ATM were included, excluding CRAB. Due to limited availability of ATM in Pakistan, only 21 patients received this regimen, enabling it as pilot study. Clinical and microbiological data were extracted from HMIS and analyzed using SPSS. Results: Among 21 treated patients, the regimen yielded an in-hospital survival rate of 85.7% and clinical improvement in 83% of survivors, with minimal adverse effects. These findings suggest meaningful clinical benefit in patients with limited therapeutic options. Conclusion: CAZ-AVI plus ATM appears to be an effective salvage therapy for carbapenem-resistant Gram-negative infections in resource-limited settings. The study also underscores a need for reliable aztreonam availability in tertiary care hospitals. Significant findings yielded from this limited data set calls for larger prospective comparative studies to further validate these results.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.